Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques
- PMID: 12388726
- PMCID: PMC136754
- DOI: 10.1128/jvi.76.22.11659-11676.2002
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques
Abstract
As most human immunodeficiency virus (HIV) infection occurs via mucosal surfaces, an important goal of vaccination may be the induction of virus-specific immune responses at mucosal sites to contain viral infection early on. Here we designed a study in macaques carrying the major histocompatibility complex class I Mamu-A(*)01 molecule to assess the capacity of the highly attenuated poxvirus NYVAC/simian immunodeficiency virus (SIV) SIV(gpe) vaccine candidate administered by the intranasal, intramuscular, or intrarectal route to induce mucosal immunity. All macaques, including one naive macaque, were exposed to SIV(mac251) by the intrarectal route and sacrificed 48 h after infection. The kinetics of immune response at various time points following immunization with NYVAC/SIV(gpe) and the anamnestic response to SIV(mac251) at 48 h after challenge were assessed in blood, in serial rectal and vaginal biopsy samples, and in tissues at euthanasia with an SIV(mac) Gag-specific tetramer. In addition, at euthanasia, antigen-specific cells producing gamma interferon or tumor necrosis factor alpha from the jejunum lamina propria were quantified in all macaques. Surprisingly, antigen-specific CD8(+) T cells were found in the mucosal tissues of all immunized macaques regardless of whether the vaccine was administered by a mucosal route (intranasal or intrarectal) or systemically. In addition, following mucosal SIV(mac251) challenge, antigen-specific responses were mainly confined to mucosal tissues, again regardless of the route of immunization. We conclude that immunization with a live vector vaccine results in the appearance of CD8(+) T-cell responses at mucosal sites even when the vaccine is delivered by nonmucosal routes.
Figures
Similar articles
-
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.J Virol. 2002 Jan;76(1):292-302. doi: 10.1128/jvi.76.1.292-302.2002. J Virol. 2002. PMID: 11739694 Free PMC article.
-
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.J Immunol. 2003 Apr 15;170(8):4281-9. doi: 10.4049/jimmunol.170.8.4281. J Immunol. 2003. PMID: 12682263
-
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.J Virol. 1998 May;72(5):4170-82. doi: 10.1128/JVI.72.5.4170-4182.1998. J Virol. 1998. PMID: 9557706 Free PMC article.
-
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.J Intern Med. 2009 Jan;265(1):67-77. doi: 10.1111/j.1365-2796.2008.02051.x. J Intern Med. 2009. PMID: 19093961 Free PMC article. Review.
-
The role of immunity in protection from mucosal SIV infection in macaques.Oral Dis. 2002;8 Suppl 2:63-8. doi: 10.1034/j.1601-0825.2002.00014.x. Oral Dis. 2002. PMID: 12164663 Review.
Cited by
-
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".J Virol. 2008 Apr;82(7):3166-80. doi: 10.1128/JVI.01634-07. Epub 2007 Nov 7. J Virol. 2008. PMID: 17989174 Free PMC article. Review. No abstract available.
-
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.J Virol. 2006 Apr;80(8):3732-42. doi: 10.1128/JVI.80.8.3732-3742.2006. J Virol. 2006. PMID: 16571790 Free PMC article.
-
Tissue competence imprinting and tissue residency of CD8 T cells.Front Immunol. 2013 Sep 17;4:283. doi: 10.3389/fimmu.2013.00283. Front Immunol. 2013. PMID: 24062749 Free PMC article. Review.
-
CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.Mucosal Immunol. 2008 Nov;1(6):497-507. doi: 10.1038/mi.2008.60. Epub 2008 Sep 17. Mucosal Immunol. 2008. PMID: 19079217 Free PMC article.
-
Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1.Front Microbiol. 2017 Oct 25;8:2091. doi: 10.3389/fmicb.2017.02091. eCollection 2017. Front Microbiol. 2017. PMID: 29118747 Free PMC article. Review.
References
-
- Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96. - PubMed
-
- Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober, and J. A. Berzofsky. 1998. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of interleukin-12. J. Clin. Investig. 102:2072-2081. - PMC - PubMed
-
- Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95:1709-1714. - PMC - PubMed
-
- Belyakov, I. M., Z. Hel, B. Kelsall, V. A. Kuznetsov, J. D. Ahlers, J. Nacsa, D. I. Watkins, T. M. Allen, A. Sette, J. Altman, R. Woodward, P. D. Markham, J. D. Clements, G. Franchini, W. Strober, and J. A. Berzofsky. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7:1320-1326. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials